Teva Eyes ‘80% Of Off-Patent Opportunities’ For Generics And Biosimilars
As Israeli Firm Identifies New Long-Term Financial Targets For 2027
Executive Summary
Teva’s president and CEO Kåre Schultz provided fresh long-term financial targets for the company in the wake of the firm agreeing in principle to settle opioid-related claims in the US – but will the architect of Teva’s restructuring remain beyond his current November 2023 contract?
You may also be interested in...
Teva: Our Biosimilars Strategy Has Been Fragmented, We Want To Be Global
Months into the job, Teva CEO Richard Francis delivered the company’s promise for a new dedicated strategy to return to growth. Funded by a portion of capital reallocated from Teva’s generics business to focus on innovative brands, the new strategy will continue to promote biosimilars, Teva has outlined.
Teva’s New CEO Francis: No Revolution, But New Strategy Will Not Be Marginal
On the final day of the annual J.P. Morgan Healthcare Conference, Richard Francis, with vast experience at Biogen and Sandoz under his belt, faced investors for the first time as Teva’s CEO, after replacing Kåre Schultz on 1 January.
Teva’s New CEO Francis: No Revolution, But New Strategy Will Not Be Marginal
On the final day of the annual J.P. Morgan Healthcare Conference, Richard Francis, with vast experience at Biogen and Sandoz under his belt, faced investors for the first time as Teva’s CEO, after replacing Kåre Schultz on 1 January.